Baidu
map

Circulation:microRNA-146a在心衰的氧化代谢中起到关键作用!

2017-06-15 MedSci MedSci原创

心血管疾病仍然是世界死亡的主要原因,心衰的发病率也在逐年上升。尽管心衰的代谢改变渐渐被学者们发现,但针对这些代谢改变的治疗方法仍缺乏。

血管疾病仍然是世界死亡的主要原因,心衰的发病率也在逐年上升。尽管心衰的代谢改变渐渐被学者们发现,但针对这些代谢改变的治疗方法仍缺乏。

本研究通过血管紧张素II灌注或横向主动脉收缩建立小鼠心负荷过载模型,microRNA-146a通过基因或者药物的方法在小鼠心肌细胞中敲除或者过表达。此外,通过腺病毒(AAV9)转染的方法在小鼠心脏中过表达microRNA-146a的下游分子二氢胆脂酰琥珀酰转移酶。

在建立的各个小鼠心负荷过载的模型中,microRNA-146a在心脏组织中都检测到有明显的上调。同样地,在主动脉狭窄的患者中,左室的活检检查也能检测到轻度地microRNA-146a升高。体内的microRNA-146a过表达能引起心肌肥大和左室功能受损,而通过基因或者药物敲除microRNA-146a后能减轻心肌肥大的过程和左室功能受损。microRNA-146a能抑制其下游二氢胆脂酰琥珀酰转移酶(DLST)的表达,而该酶是三羧酸循环的关键酶。在心脏负荷过载的野生型小鼠中,DLST蛋白的水平显着下降,从而引起氧化代谢也下降,而在microRNA-146a敲除小鼠中,DLST蛋白的水平和氧化代谢水平则维持正常。此外,DLST的过表达能保护心肌肥大和左室功能受损。

本研究证实了microRNA-146a和其下游分子DLST在左室功能中起到重要作用。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2084231, encodeId=e2c72084231c3, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Apr 29 11:36:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857465, encodeId=7613185e465ff, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Feb 19 16:36:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793397, encodeId=edae1e9339761, content=<a href='/topic/show?id=04fd15533ef' target=_blank style='color:#2F92EE;'>#RNA-146#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15533, encryptionId=04fd15533ef, topicName=RNA-146)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Thu Apr 12 07:36:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435694, encodeId=7a96143569417, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jun 17 05:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2018-04-29 xjy02
  2. [GetPortalCommentsPageByObjectIdResponse(id=2084231, encodeId=e2c72084231c3, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Apr 29 11:36:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857465, encodeId=7613185e465ff, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Feb 19 16:36:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793397, encodeId=edae1e9339761, content=<a href='/topic/show?id=04fd15533ef' target=_blank style='color:#2F92EE;'>#RNA-146#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15533, encryptionId=04fd15533ef, topicName=RNA-146)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Thu Apr 12 07:36:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435694, encodeId=7a96143569417, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jun 17 05:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2084231, encodeId=e2c72084231c3, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Apr 29 11:36:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857465, encodeId=7613185e465ff, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Feb 19 16:36:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793397, encodeId=edae1e9339761, content=<a href='/topic/show?id=04fd15533ef' target=_blank style='color:#2F92EE;'>#RNA-146#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15533, encryptionId=04fd15533ef, topicName=RNA-146)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Thu Apr 12 07:36:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435694, encodeId=7a96143569417, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jun 17 05:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2084231, encodeId=e2c72084231c3, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Apr 29 11:36:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857465, encodeId=7613185e465ff, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Feb 19 16:36:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793397, encodeId=edae1e9339761, content=<a href='/topic/show?id=04fd15533ef' target=_blank style='color:#2F92EE;'>#RNA-146#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15533, encryptionId=04fd15533ef, topicName=RNA-146)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Thu Apr 12 07:36:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435694, encodeId=7a96143569417, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jun 17 05:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2017-06-17 zhouqu_8

相关资讯

BMJ Open:血纤维蛋白原水平与心血管事件有关

阜外医院李建军教授等开展的一项前瞻性观察性研究显示,在我国合并2型糖尿病的稳定性冠心病患者中,血纤维蛋白原水平升高与心血管事件风险增加独立相关。 在单因素回归分析中,血纤维蛋白原水平每升高1个标准差,心血管事件风险增加25%。

Nature Biomedical Engineering:3D打印将细胞排列成特定图案,为损伤血管打“补丁”

血管狭窄、硬化或者堵塞引起的组织缺血经常导致心脏病发作,中风,坏疽等严重疾病。虽然目前的手术可以修复大血管出现的问题,但治疗那些比较微小或已被治疗损伤过的血管仍然十分复杂。近日,来自波士顿大学等机构的研究人员开发一种新方法,利用注入内皮细胞的3D打印血管补片,生长出健康血管。该研究发表在新一期的Nature Biomedical Engineering期刊上。

坎格列净减少心血管事件,增加截肢风险——CANVAS研究结果公布

CANVAS研究结果的公布,将2017年ADA年会的气氛推向高潮。一如预期,该研究结果显示,新型降糖药物SGLT-2抑制剂坎格列净治疗可以显着降低受试者主要复合心血管终点事件发生率。然而,本研究同时发现该药明显增加了截肢风险。

JACC:联合抗凝治疗方案不能降低房颤患者心梗发生的风险!

房颤患者的血栓栓塞事件比如中风和心梗的发生风险要更高。尽管对于房颤患者来说,抗凝药物的效果要优于预防卒中的抗血小板药物,但目前用来预防心梗的最佳抗凝方案尚未明确。近日,在国际心血管权威杂志JACC上发表了一篇临床研究,旨在根据抗凝治疗的方案探索了房颤患者首次心梗的发生率,并评估了卒中和出血的风险。

Lancet Diabetes Endo:二甲双胍对I型糖尿病患者心血管和代谢的影响

二甲双胍对于中老年I型糖尿病患者的血糖控制无明显作用但其存在广泛的心血管风险预防效果

JACC:β-受体阻滞剂和心率对心衰患者预后的影响!

目前,对于伴有窦性节律或房颤的心衰患者,心率与其死亡率的关系尚未明确。近日,在国际心血管权威杂志JACC上发表了一篇荟萃分析,旨在分析探讨随机对照试验比较β-受体阻滞剂和安慰剂对心力衰竭患者心率的预后重要性。

Baidu
map
Baidu
map
Baidu
map